Articles related to BLEEDING/BLOOD DISORDERS

Thrombotic events occurred earlier with Andexxa than usual care (median of 3.5 days vs 16 days). Fifty-three percent of Andexxa-treated patients who experienced a thrombotic event had the event during the first 3 days.

Prior to CDC’s Sickle Cell Data Collection program, the actual number of Americans living with sickle cell disease was unknown, with current estimates of 100,000 patients based on systematic data collection efforts now at risk.

Vaginal fluid collection via tampon under clinical supervision followed by bisulfite conversion and long-probe quantitative amplified signal assays for methylated DNA marker analysis.

Hemoglobin disorders represent the single largest category of genetic disorders in the United States after chromosomal disorders, yet there is no systematic approach to managing them despite excellent guidelines from NHLBI, ASH, and NASCC.

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.

Cancer correlation analysis reveals that persistent thrombocytosis at six months carries an 18.1% cancer risk in males and 10.1% in females, with lung and colorectal malignancies predominating.